, Volume 77, Issue 13, pp 1473–1480 | Cite as

Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT

  • Yahiya Y. SyedEmail author
Adis Drug Evaluation


Lenalidomide (Revlimid®) is an immunomodulatory drug with multiple mechanisms of action against multiple myeloma. It is a thalidomide analogue, with improved potency and reduced toxicity compared with thalidomide. In the EU and USA, lenalidomide monotherapy is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem-cell transplantation (ASCT). In the pivotal, phase 3 IFM 2005-02 and CALGB 100104 trials, lenalidomide maintenance therapy after ASCT administered until disease progression significantly prolonged progression-free survival (PFS; primary endpoint) relative to placebo in patients with newly diagnosed multiple myeloma. These results are generally supported by those of the phase 3 GIMEMA and Myeloma XI trials. Lenalidomide maintenance therapy significantly prolonged overall survival in CALGB 100104 but not in IFM 2005-02. However, a meta-analysis of patient-level data from IFM 2005-02, CALGB 100104 and GIMEMA showed an overall survival benefit with this therapy. Lenalidomide maintenance therapy had a manageable tolerability profile in the pivotal trials. Grade 3/4 haematological adverse events and grade 3 nonhaematological adverse events were more common with lenalidomide than with placebo. Lenalidomide increased the risk of a second primary cancer, but the survival benefits outweigh this risk. In conclusion, lenalidomide maintenance therapy after ASCT until disease progression prolongs PFS and overall survival in patients with newly diagnosed multiple myeloma. Therefore, lenalidomide offers a valuable maintenance treatment option for this population.



During the peer review process, the manufacturer of lenalidomide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Yahiya Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at


  1. 1.
    Ahn IE, Mailankody S. Controversies in multiple myeloma: evidence-based update. Semin Oncol. 2016;43(6):666–75.CrossRefGoogle Scholar
  2. 2.
    National comprehensive cancer network. NCCN clinical practice guidelines in oncology (NCCN guidelines) version 3.2017: multiple myeloma. 2017. Accessed 27 Jul 2017.
  3. 3.
    Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017. doi: 10.1093/annonc/mdx096.CrossRefGoogle Scholar
  4. 4.
    Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.CrossRefGoogle Scholar
  5. 5.
    McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.CrossRefGoogle Scholar
  6. 6.
    Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009. doi: 10.1186/1756-8722-2-36.CrossRefGoogle Scholar
  7. 7.
    Revlimid® (lenalidomide): summary of product characteristics. 2017. Accessed 27 Jul 2017.
  8. 8.
    Revlimid® (lenalidomide): US prescribing Information. 2017. Accessed 27 Jul 2017.
  9. 9.
    Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71(5):625–49.CrossRefGoogle Scholar
  10. 10.
    McCormack PL. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. Drugs Aging. 2015;32(5):409–18.CrossRefGoogle Scholar
  11. 11.
    Syed YY, Scott LJ. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. Drugs. 2013;73(11):1183–96.CrossRefGoogle Scholar
  12. 12.
    Reske T, Fulciniti M, Munshi NC. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol. 2010;27(Suppl 1):S7–13.CrossRefGoogle Scholar
  13. 13.
    Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803–9.CrossRefGoogle Scholar
  14. 14.
    Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.CrossRefGoogle Scholar
  15. 15.
    Kramer I, Engelhardt M, Fichtner S, et al. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662 (1–9).CrossRefGoogle Scholar
  16. 16.
    Brissot E, Clavert A, Blin N, et al. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. Leukemia. 2015;29(10):2098–100.CrossRefGoogle Scholar
  17. 17.
    Clave E, Douay C, Coman T, et al. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma. 2014;55(8):1788–95.CrossRefGoogle Scholar
  18. 18.
    Jones JR, Weinhold N, Chavan SS, et al. The impact of maintenance lenalidomide on the mutational status of the myeloma clone at relapse in the NCRI myeloma XI trial for newly diagnosed multiple myeloma patients (NDMM) [abstract no. 4412]. Blood. 2016;128(22).Google Scholar
  19. 19.
    Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32(25):2712–7.CrossRefGoogle Scholar
  20. 20.
    Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28(5):800–7.CrossRefGoogle Scholar
  21. 21.
    Takamatsu H, Munemoto S, Murata R, et al. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Anticancer Res. 2013;33(12):5681–5.PubMedGoogle Scholar
  22. 22.
    Silvennoinen R, Anttila P, Saily M, et al. A prospective phase 2 study to assess immunophenotypic remission after lenalidomide-based induction followed by ASCT and lenalidomide maintenance in patients with newly diagnosed multiple myeloma [abstract no. 1977]. Blood. 2015;126(23).Google Scholar
  23. 23.
    Reece D, Rodriguez GP, Pantoja M, et al. Myeloma Canada Research Network (MCRN)-001 ASCT study of busulfan + melphalan (BuMel) conditioning followed by lenalidomide (Len) maintenance: updated results including serial minimal residual disease (MRD) and involved serum Hevylite™ chain (HLC) ratio assessments [abstract no. 4632]. Blood. 2016;128(22).Google Scholar
  24. 24.
    Guglieri-Lopez B, Perez-Pitarch A, Moes DJ, et al. Population pharmacokinetics of lenalidomide in multiple myeloma patients. Cancer Chemother Pharmacol. 2017;79(1):189–200.CrossRefGoogle Scholar
  25. 25.
    Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56(2):139–52.CrossRefGoogle Scholar
  26. 26.
    Hou J, Du X, Jin J, et al. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. J Hematol Oncol. 2013. doi: 10.1186/1756-8722-6-41.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.CrossRefGoogle Scholar
  28. 28.
    Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study [abstract no. 1143]. Blood. 2016;128(22).Google Scholar
  29. 29.
    McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017. doi: 10.1200/JCO.2017.72.6679.CrossRefGoogle Scholar
  30. 30.
    Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial [abstract no. 406]. Blood. 2013;122(21).Google Scholar
  31. 31.
    Ye X, Huang J, Pan Q, et al. Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials. PLoS One. 2013. doi: 10.1371/journal.pone.0072635.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Holstein SA, Owzar K, Richardson PG, et al. Updated analysis of CALGB/ECOG/BMT CTN 100104: lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM) [abstract no. 8523 plus poster]. J Clin Oncol. 2015;33(Suppl.).Google Scholar
  33. 33.
    Abonour R, Durie BGM, Jagannath S, et al. Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the connect MM disease registry [abstract no. 537]. Blood. 2016;128(22).Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations